Public medical-device company (Nasdaq NPCE), maker of the RNS System for drug-resistant focal epilepsy. Incorporated in 1997; some operating histories use 1999. Joel Becker became CEO in July 2023.
Founded 1997
team@apexlogos.ai · 7 hours ago
RELATED team@apexlogos.ai · 7 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: NeuroPace. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts.
Part 1/1
# NeuroPace
Accessed: 2026-10-06. Research report for human review; no database changes made. Direct image URLs are extracted source assets, not invented filenames. Funding ledger is verified events found, not a complete lifetime total.
## Identity and pasted claims
[NeuroPace, Inc.](https://www.neuropace.com/ ) is a public operating medical-device company, Nasdaq NPCE, based in Mountain View, California. Delaware incorporation November 19, 1997 is stated in [2021 Form 10-K](https://www.sec.gov/Archives/edgar/data/1528287/000152828722000006/npce-20211231.htm ); commercial histories sometimes use 1999, which should be recorded separately rather than replacing incorporation date.
The RNS System for drug-resistant focal epilepsy is real. Pasted Mountain View and active company classification pass. Mike Favet is **former** CEO: Joel Becker became CEO July 10, 2023 under the [official transition](https://investors.neuropace.com/news/news-details/2023/NeuroPace-Announces-CEO-Transition-06-28-2023/default.aspx ). The $250M+ pasted total lacks a defined basis; equity, convertibles, IPO proceeds and refinancing must be stored separately. RNS generalized epilepsy expansion remained subject to FDA review in [2026 guidance](https://investors.neuropace.com/news/news-details/2026/NeuroPace-Receives-FDA-Guidance-on-PMA-Supplement-for-Indication-Expansion-into-Idiopathic-Generalized-Epilepsy/default.aspx ).
## Images and public leadership
Logo: https://www.neuropace.com/wp-content/uploads/2021/01/logo-main.png — official website header; alternative press-kit asset https://www.neuropace.com/wp-content/uploads/2020/12/NeuroPace-Logo-Horiz-rgb-med.png from [press kit](https://www.neuropace.com/about-neuropace/press-kit/ ).
| Person | Role / currency | Profile and evidence | Direct pfp URL |
|---|---|---|---|
| Joel Becker | Current CEO | [self-profile](https://www.linkedin.com/in/joel-becker-9225bb90 ); [2026 annual report](https://www.sec.gov/Archives/edgar/data/1528287/000114036126015899/ny20064129x3_ars.pdf ); [management](https://investors.neuropace.com/corporate-governance/management/ ) | https://media.licdn.com/dms/image/v2/C4E03AQHNIcQxw3cCNA/profile-displayphoto-shrink_200_200/profile-displayphoto-shrink_200_200/0/1556721225903?e=2147483647&v=beta&t=nbO7aNb_9-bPhQwa3OG-KCN55btNzS96dJTtsSnZihk (self-profile HTML, signed URL) |
| Martha Morrell | Current chief medical officer | [2026 annual report](https://www.sec.gov/Archives/edgar/data/1528287/000114036126015899/ny20064129x3_ars.pdf ); [management](https://investors.neuropace.com/corporate-governance/management/ ) | https://profiles.stanford.edu/proxy/api/cap/profiles/6968/resources/profilephoto/350x350.1753235414304.jpg — [official university portrait](https://profiles.stanford.edu/martha-morrell ) |
| Patrick Williams | Current CFO | [2026 annual report](https://www.sec.gov/Archives/edgar/data/1528287/000114036126015899/ny20064129x3_ars.pdf ); [management](https://investors.neuropace.com/corporate-governance/management/ ) | Unavailable: IR management page returned 403 on direct HTML fetch; web-rendered page and press kit did not expose an attributable portrait URL. |
| Frank Fischer | Board chair; former CEO | [2026 annual report](https://www.sec.gov/Archives/edgar/data/1528287/000114036126015899/ny20064129x3_ars.pdf ); [management](https://investors.neuropace.com/corporate-governance/management/ ) | Unavailable: IR management page returned 403 on direct HTML fetch; web-rendered page and press kit did not expose an attributable portrait URL. |
Founders were not conclusively validated from a primary founding record in this pass. Do not import the Fischell family founder associations solely from third-party company aggregators. Chris Reese is listed SVP Sales in the [March 2026 investor deck](https://s21.q4cdn.com/490582783/files/doc_presentations/2026/Mar/03/NPCE-Investor-Presentation.pdf ); direct portrait unavailable.
## Financing ledger
| Date | Amount / currency | Type | Named lead / participants | Evidence |
|---|---|---|---|---|
| 2017-10-24 | USD74M | Equity | KCK Group and OrbiMed co-lead | [Company release](https://investors.neuropace.com/news/news-details/2017/NeuroPace-Closes-74-Million-Equity-Funding-to-Accelerate-Patient-Access-to-the-Worlds-First-Brain-Responsive-Neurostimulation-System-to-Treat-Epilepsy-10-24-2017/default.aspx ) |
| 2020-08-31 | USD67M announced: 33M new equity + 34M prior-round convertible debt | Mixed; separate components | Accelmed lead; unnamed strategic, Revelation Partners, Soleus Capital, KCK, OrbiMed. Additional 27M second-tranche commitment is not additive to received cash | [Company release](https://www.neuropace.com/press-release/neuropace-raises-67-million-financing-commercial-expansion-rns-system/ ) |
| 2021-04-26 | USD117.3M gross / USD105.5M net | IPO, not private venture round | 6.9M shares at USD17 including full underwriter option | [IPO close](https://investors.neuropace.com/news/news-details/2021/NeuroPace-Inc--Announces-Closing-of-Initial-Public-Offering-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares-04-26-2021/default.aspx ) |
| 2021-05 | USD4.5M | NIH research grant, not equity | Lennox-Gastaut clinical-study expenses; expenses funded through 2025 | [2025 Form10-K](https://www.sec.gov/Archives/edgar/data/1528287/000152828726000011/npce-20251231.htm ) |
| 2025-06-04 | Up to USD75M: 60M term loan +15M revolver | Debt facility / CRG refinancing | MidCap Financial; availability is not fully drawn new funding | [Company release](https://investors.neuropace.com/news/news-details/2025/NeuroPace-Secures-Up-to-75-Million-in-Debt-Financing-06-04-2025/default.aspx ) |
## Review / import decision
New entity `NeuroPace` is appropriate following review. Import Joel as CEO, retain Favet as former, preserve incorporation date evidence and source rounds individually. Lifetime total and founder associations require further documentation; photographs need a retrievable authoritative team source before image import. SHOW MORE
Joel BeckerCEO
Martha Morrellchief medical officer